On December 5, 2023, Peter K Honig, M.D., MPH, a member of the Board of Directors of Karyopharm Therapeutics Inc., notified the Company of his resignation from the Board, effective as of December 31, 2023. Dr. Honig?s resignation is due to competing professional demands and not the result of any disagreement with the Company on any matter relating to the Company?s operations, policies or practices.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.09 USD | +1.87% | -3.54% | +26.01% |
May. 08 | Earnings Flash (KPTI) KARYOPHARM THERAPEUTICS Reports Q1 Revenue $33.1M, vs. Street Est of $34.5M | MT |
May. 08 | Transcript : Karyopharm Therapeutics Inc., Q1 2024 Earnings Call, May 08, 2024 |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+26.01% | 128M | |
+3.91% | 109B | |
+10.87% | 105B | |
+1.28% | 22.25B | |
-13.14% | 22.09B | |
-7.05% | 18.68B | |
-38.36% | 17.58B | |
-10.66% | 16.85B | |
+3.75% | 13.76B | |
+36.70% | 12.46B |
- Stock Market
- Equities
- KPTI Stock
- News Karyopharm Therapeutics Inc.
- Karyopharm Therapeutics Inc. Announces Resignation of Peter K Honig as Member of the Board of Directors